VERTICAL ANALYSIS

BY
ANANTHA BHAIRAVI M(1913123)
PGDM-I YEAR- B
MEDIUM MARKET CAPITALIZATION
Market capitalization refers to the total dollar market
value of a company's outstanding shares. Commonly referred
to as "market cap," it is calculated by multiplying a
company's shares outstanding by the current market price of
one share.
• IT- Industry-MphasiS
• Financial Services- Mahindra and Mahindra Finance
• Automobile Industry-Ashok Leyland
• Pharmaceuticals Industry- Glenmark Pharmaceuticals
 LET’S KNOW!
• ASHOK LEYLAND: Ashok Leyland is an Indian automobile company
headquartered in Chennai, India. It is owned by the Hinduja Group. Founded
in 1948, it is the second largest commercial vehicle manufacturer in India,
fourth largest manufacturer of buses in the world and 10th largest
manufacturer of trucks globally.

Revenue  ₹21,332 Crores

Net Income ₹1,223 Crores
Market Capitalization ₹ 17950.75 Crores
 LET’S KNOW!
• MPHASIS: Mphasis is an IT services company based in Bangalore, India.
The company provides infrastructure technology and applications
outsourcing services, as well as architecture guidance, application
development and integration, and application management services.

Revenue ₹6,377 Crores

Net Income ₹837 Crores
Market Capitalization ₹17932.6 Crores
 LET’S KNOW!
• GLENMARK PHARMACEUTICALS: Glenmark Pharmaceuticals is a
pharmaceutical company headquartered in Mumbai, India that was founded
in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical
ingredient manufacturer; he named the company after his two sons. The
company initially sold its products in India, Russia, and Africa.

Net Income ₹ 6780.48 Crores

Revenue ₹ 6304.87 Crores
Market Capitalization ₹ 12119.12 Crores
 LET’S KNOW!
• MAHINDRA AND MAHINDRA FINANCIALS: Mahindra & Mahindra
Financial Services Limited is a Rural NBFC headquartered in Mumbai,
India. It is amongst the top tractor financer in India and offers a wide range
of financial products to address varied customer requirements

Net Income ₹ 10430.9 Crores

Revenue ₹49,5300 million
Market Capitalization ₹18,591 Crores
 STANDALONE BALANCE SHEET
As on March'19 Ashok Leyland Mahindra and Mahindra Glenmark Mphasis
Financials Pharmaceuticals

Standalone Balance sheet(in        

Crores)
         
EQUITIES AND LIABILITIES      
SHAREHOLDER'S FUNDS      
Equity Share Capital 293.55 122.98 28.22 186.23
Total Share Capital 293.55 122.98 28.22 186.23
Revaluation Reserves 0 0 0 0
Reserves and Surplus 8038.88 10785.05 11913.87 3077.4
Total Reserves and Surplus 8038.88 10785.05 11913.87 3077.4
Total Shareholder’s Funds 8332.43 10908.02 11942.09 3263.62
NON-CURRENT LIABILITIES      
Long Term Borrowings 298.4 31545.4 2831.45 0
Deferred Tax Liabilities [Net] 249.73 0 0 0
Other Long Term Liabilities 305.25 99.2 88.51 90.97
Long Term Provisions 249.63 206.53 0 0
Total Non-Current Liabilities 1103.01 31851.13 2919.96 90.97
CURRENT LIABILITIES      
Short Term Borrowings 100 21301.53 303.03 238.31
Trade Payables 5018.93 1013.65 1667.66 332.6
Other Current Liabilities 2867.26 2003.65 224.63 343.89
Short Term Provisions 802.77 0 85.33 8.32
Total Current Liabilities 8788.96 24318.84 2280.65 923.12
Total Capital And Liabilities 18224.4 67077.99 17142.7 4277.71
 STANDALONE BALANCE SHEET
Standalone Balance Sheet Ashok Mahindra and Mahindra Finance Glenmark Pharmaceuticals Mphasis
Leyland
ASSETS      
NON-CURRENT ASSETS      
Tangible Assets 4805.98 132.5 1699.68 88.61
Intangible Assets 808.53 30.56 0 9.04
Capital Work-In-Progress 274.64 0 0 1.58
Intangible Assets Under Development 382.98 0 0 1.34
Fixed Assets 6272.13 163.06 1699.68 100.56
Non-Current Investments 2636.5 0 3268.75 1498.23
Deferred Tax Assets [Net] 0 371.73 712.13 71.2
Long Term Loans And Advances 31.71 0 6263.93 70.21
Other Non-Current Assets 1097.72 359.17 57.06 586.57
Total Non-Current Assets 10038.06 893.96 12001.54 2326.76

CURRENT ASSETS      
Current Investments 0 3791.7 0 586.47
Inventories 2684.67 0 911.21 0
Trade Receivables 2505.53 5.19 2087.13 501.75
Cash And Cash Equivalents 1373.59 958.49 256.48 146.53
Short Term Loans And Advances 22.46 61249.63 0 103.22
OtherCurrentAssets 1600.09 179.02 1886.33 612.97
Total Current Assets 8186.34 66184.03 5141.15 1950.95
Total Assets 18224.4 67077.99 17142.7 4277.71
 VERTICAL ANALYSIS
As on March'19 Ashok Leyland Mahindra and Mahindra Glenmark Mphasis
Financials Pharmaceuticals

Vertical Analysis (in %)        

         
EQUITIES AND LIABILITIES        
SHAREHOLDER'S FUNDS        
Equity Share Capital 1.61 0.1833 0.164 4.35
Total Share Capital 1.61 0.1833 0.164 4.35
Revaluation Reserves 0 0 0 0
Reserves and Surplus 44.11 16.078 71.9 71.9
Total Reserves and Surplus 44.11 16.078 71.9 71.9
Total Shareholders Funds 45.72 16.26 76.29 76.29
NON-CURRENT LIABILITIES      
Long Term Borrowings 1.63 47.027 16.51 0
Deferred Tax Liabilities [Net] 1.37 0 0 0
Other Long Term Liabilities 1.67 0.147 0.51 2.12
Long Term Provisions 1.36 0.307 0 0
Total Non-Current Liabilities 6.05 47.48 17.033 2.12
CURRENT LIABILITIES        
Short Term Borrowings 0.54 31.75 1.76 5.57
Trade Payables 27.5 1.511 9.728 7.77
Other Current Liabilities 15.73 2.98 1.31 8.039
Short Term Provisions 4.405 0 0.49 0.19
Total Current Liabilities 48.22 36.25 13.3 21.57
Total Capital And Liabilities 100 100 100 100
 VERTICAL ANALYSIS
VERTICAL ANALYSIS (in %) Ashok Leyland Mahindra and Mahindra Glenmark Mphasis
Finance Pharmaceuticals

ASSETS        
NON-CURRENT ASSETS        
Tangible Assets 26.37 0.19 9.91 2.07
Intangible Assets 4.43 0.04 0 0.211
Capital Work-In-Progress 1.506 0 0 0.03
Intangible Assets Under Development 2.1 0 0 0.0313

Fixed Assets 34.4 0.24 9.91 2.35

Non-Current Investments 14.4 0 19.06 35.02
Deferred Tax Assets [Net] 0 0.554 4.15 1.664
Long Term Loans And Advances 0.17 0 36.53 1.64

Other Non-Current Assets 6.023 0.535 0.33 13.71

Total Non-Current Assets 55.08 1.332 70 54.39
CURRENT ASSETS        
Current Investments 0 5.65 0 13.7
Inventories 14.73 0 5.3 0
Trade Receivables 13.7 0..0077 12.17 11.729
Cash And Cash Equivalents 7.5 1.42 14.96 3.425
Short Term Loans And Advances 0.12 91.31 0 2.41

OtherCurrentAssets 8.77 0.266 11 14.32

Total Current Assets 44.91 98.66 29.99 45.6
Total Assets 100 100 100 100
COMPANY’S INDIVIDUAL BALANCE SHEET
AND VERTICAL ANALYSIS
 ASHOK LEYLAND(MARCH ‘
19)
STANDALONE BALANCE SHEET ------------------- in Rs. Cr. ------------- VERTICAL ANALYSIS(in %)

   (MARCH ‘ 19)  
EQUITIES AND LIABILITIES  
SHAREHOLDER'S FUNDS  
Equity Share Capital 293.55 1.61
Total Share Capital 293.55 1.61
Revaluation Reserves 0 0
Reserves and Surplus 8038.88 44.11
Total Reserves and Surplus 8038.88 44.11
Total Shareholders Funds 8332.43 45.72
NON-CURRENT LIABILITIES  
Long Term Borrowings 298.4 1.63
Deferred Tax Liabilities [Net] 249.73 1.37
Other Long Term Liabilities 305.25 1.67
Long Term Provisions 249.63 1.36
Total Non-Current Liabilities 1103.01 6.05
CURRENT LIABILITIES  
Short Term Borrowings 100 0.54
Trade Payables 5018.93 27.5
Other Current Liabilities 2867.26 15.73
Short Term Provisions 802.77 4.405
Total Current Liabilities 8788.96 48.22
Total Capital And Liabilities 18224.4 100
 ASHOK
ASSETS LEYLAND
 VERTICAL ANALYSIS (in %)
NON-CURRENT ASSETS  
Tangible Assets 4805.98 26.37
Intangible Assets 808.53 4.43
Capital Work-In-Progress 274.64 1.506
Intangible Assets Under Development 382.98 2.1
Fixed Assets 6272.13 34.4
Non-Current Investments 2636.5 14.4
Long Term Loans And Advances 31.71 0.17
Other Non-Current Assets 1097.72 6.023
Total Non-Current Assets 10038.06 55.08
CURRENT ASSETS  
Current Investments 0 0
Inventories 2684.67 14.73
Trade Receivables 2505.53 13.7
Cash And Cash Equivalents 1373.59 7.5
Short Term Loans And Advances 22.46 0.12
OtherCurrentAssets 1600.09 8.77
Total Current Assets 8186.34 44.91
Total Assets 18224.4 100
 ASHOK
OTHER ADDITIONAL INFORMATION
LEYLAND
 
CONTINGENT LIABILITIES, COMMITMENTS  
Contingent Liabilities 927.91  
CIF VALUE OF IMPORTS  
Raw Materials 0  
Stores, Spares And Loose Tools 0  
Trade/Other Goods 0  
Capital Goods 0  
EXPENDITURE IN FOREIGN EXCHANGE  
Expenditure In Foreign Currency 237.47  
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS  
Dividend Remittance In Foreign Currency -  
EARNINGS IN FOREIGN EXCHANGE  
FOB Value Of Goods 1486.88  
Other Earnings 74.58  
BONUS DETAILS  
Bonus Equity Share Capital 139.26  
NON-CURRENT INVESTMENTS  
Non-Current Investments Quoted Market Value -  
Non-Current Investments Unquoted Book Value 3292.87  
CURRENT INVESTMENTS  
Current Investments Quoted Market Value -  
Current Investments Unquoted Book Value -  
 INFERENCE
Major contributions in the company’s capital
• Liabilities - Trade Payables(44.11)
• Assets –
• Inventories(14.37)
• Tangible Assets(26.37)
• Equity - Reserves and Surplus(27.5)
MAHINDRA & MAHINDRA FINANCIAL SERVICES(MARCH ‘
STANDALONE BALANCE SHEET ------------- in Rs. Cr. ------------ VERTICAL ANALYSIS(in %)
19)
EQUITIES AND LIABILITIES  
SHAREHOLDER'S FUNDS  
Equity Share Capital 122.98 0.1833
Total Share Capital 122.98 0.1833
Reserves and Surplus 10785.05 16.078
Total Reserves and Surplus 10785.05 16.078
Total Shareholders Funds 10908.02 16.26
NON-CURRENT LIABILITIES  
Long Term Borrowings 31545.4 47.027
Other Long Term Liabilities 99.2 0.147
Long Term Provisions 206.53 0.307
Total Non-Current Liabilities 31851.13 47.48
CURRENT LIABILITIES  
Short Term Borrowings 21301.53 31.75
Trade Payables 1013.65 1.511
Other Current Liabilities 2003.65 2.98
Short Term Provisions 0 0
Total Current Liabilities 24318.84 36.25
Total Capital And Liabilities 67077.99 100
 MAHINDRA & MAHINDRA FINANCIAL
ASSETS
NON-CURRENT ASSETS
SERVICES  VERTICAL ANALYSIS (in %)

 
Tangible Assets 132.5 0.19
Intangible Assets 30.56 0.04
Capital Work-In-Progress 0 0
Fixed Assets 163.06 0.24
Non-Current Investments 0 0
Deferred Tax Assets [Net] 371.73 0.554
Long Term Loans And Advances 0 0
Other Non-Current Assets 359.17 0.535
Total Non-Current Assets 893.96 1.332
CURRENT ASSETS  
Current Investments 3791.7 5.65
Trade Receivables 5.19 0..0077
Cash And Cash Equivalents 958.49 1.42
Short Term Loans And Advances 61249.63 91.31
OtherCurrentAssets 179.02 0.266
Total Current Assets 66184.03 98.66
Total Assets 67077.99 100
 MAHINDRA & MAHINDRA FINANCIAL
CONTINGENT LIABILITIES,SERVICES
OTHER ADDITIONAL INFORMATION
COMMITMENTS
Contingent Liabilities 1081.11
CIF VALUE OF IMPORTS
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency 0
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency -
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods -
Other Earnings -
BONUS DETAILS
Bonus Equity Share Capital -
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value -
Non-Current Investments Unquoted Book Value -
CURRENT INVESTMENTS
Current Investments Quoted Market Value -
Current Investments Unquoted Book Value 3791.7
 INFERENCE
Major contributions in the company’s capital
• Liabilities – long term borrowings(47.027)
Short term borrowings(31.75)
• Assets - Short Term Loans And Advances (91.3)
• Equity - Reserves and Surplus(16.078)
 GLENMARK PHARMACEUTICALS(MARCH ‘ 19)
STANDALONE BALANCE SHEET ----------- in Rs. Cr. -----------  VERTICAL ANALYSIS(in %)
EQUITIES AND LIABILITIES  
SHAREHOLDER'S FUNDS  
Equity Share Capital 28.22 0.164618176
Total Share Capital 28.22 0.164618176
Reserves and Surplus 11913.87 69.49821207
Total Reserves and Surplus 11913.87 69.49
Total Shareholders Funds 11942.09 69.66
NON-CURRENT LIABILITIES  
Long Term Borrowings 2831.45 16.51
Deferred Tax Liabilities [Net] 0 0
Other Long Term Liabilities 88.51 0.51
Total Non-Current Liabilities 2919.96 17.033
CURRENT LIABILITIES  
Short Term Borrowings 303.03 1.76
Trade Payables 1667.66 9.728
Other Current Liabilities 224.63 1.31
Short Term Provisions 85.33 0.49
Total Current Liabilities 2280.65 13.3
Total Capital And Liabilities 17142.7 100
 GLENMARK PHARMACEUTICALS
ASSETS  VERTICAL ANALYSIS(in %)

NON-CURRENT ASSETS  
Tangible Assets 1699.68 9.91
Intangible Assets 0 0
Capital Work-In-Progress 0 0
Intangible Assets Under Development 0 0
Fixed Assets 1699.68 9.91
Non-Current Investments 3268.75 19.06
Deferred Tax Assets [Net] 712.13 4.15
Long Term Loans And Advances 6263.93 36.53
Other Non-Current Assets 57.06 0.33
Total Non-Current Assets 12001.54 70
CURRENT ASSETS  
Inventories 911.21 5.3
Trade Receivables 2087.13 12.17
Cash And Cash Equivalents 256.48 14.96
Short Term Loans And Advances 0 0
OtherCurrentAssets 1886.33 11
Total Current Assets 5141.15 29.99
Total Assets 17142.7 100
 GLENMARK PHARMACEUTICALS
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities 0
CIF VALUE OF IMPORTS
Raw Materials 0
Capital Goods 0
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency 0
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency -
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods -
Other Earnings -
BONUS DETAILS
Bonus Equity Share Capital 0
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value -
Non-Current Investments Unquoted Book Value -
CURRENT INVESTMENTS
Current Investments Quoted Market Value -
Current Investments Unquoted Book Value -
 INFERENCE
Major contributions in the company’s capital
• Liabilities – long term borrowings(16.51)
Trade Payable(9.72)
• Assets - Long Term Loans And Advances (36.53)
Non-Current Investments(19.06)
• Equity - Reserves and Surplus(69.498 )
 MPHASIS IT SERVICE MANAGEMENT(MARCH ‘ 19)
STANDALONE BALANCE SHEET ------------ in Rs. Cr. ----------- VERTICAL ANALYSIS(in %)
EQUITIES AND LIABILITIES  
SHAREHOLDER'S FUNDS  
Equity Share Capital 186.23 4.35
Total Share Capital 186.23 4.35
Reserves and Surplus 3077.4 71.9
Total Reserves and Surplus 3077.4 71.9
Total Shareholders Funds 3263.62 76.29
NON-CURRENT LIABILITIES  
Other Long Term Liabilities 90.97 2.12
Long Term Provisions 0 0
Total Non-Current Liabilities 90.97 2.12
CURRENT LIABILITIES  
Short Term Borrowings 238.31 5.57
Trade Payables 332.6 7.77
Other Current Liabilities 343.89 8.039
Short Term Provisions 8.32 0.19
Total Current Liabilities 923.12 21.57
Total Capital And Liabilities 4277.71 100
 MPHASIS IT SERVICE
ASSETS
NON-CURRENT ASSETS
MANAGEMENT
 VERTICAL ANALYSIS (in %)
 
Tangible Assets 88.61 2.07
Intangible Assets 9.04 0.211
Capital Work-In-Progress 1.58 0.03
Intangible Assets Under Development 1.34 0.0313
Fixed Assets 100.56 2.35
Non-Current Investments 1498.23 35.02
Deferred Tax Assets [Net] 71.2 1.664
Long Term Loans And Advances 70.21 1.64
Other Non-Current Assets 586.57 13.71
Total Non-Current Assets 2326.76 54.39
CURRENT ASSETS  
Current Investments 586.47 13.7
Inventories 0 0
Trade Receivables 501.75 11.729
Cash And Cash Equivalents 146.53 3.425
Short Term Loans And Advances 103.22 2.41
OtherCurrentAssets 612.97 14.32
Total Current Assets 1950.95 45.6
Total Assets 4277.71 100
 MPHASIS IT SERVICE
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
MANAGEMENT
Contingent Liabilities 1175.88
CIF VALUE OF IMPORTS
Capital Goods 0
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency 520.4
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency -
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods -
Other Earnings 2990.3
BONUS DETAILS
Bonus Equity Share Capital 129.3
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market Value -
Non-Current Investments Unquoted Book Value 1422.88
CURRENT INVESTMENTS
Current Investments Quoted Market Value -
Current Investments Unquoted Book Value 379.05
 INFERENCE
Major contributions in the company’s capital
• Liabilities - Other Current Liabilities (8.039)
• Assets - Non-Current Investments(35.02)
• Equity - Reserves and Surplus(71.9)
VERTICAL ANALYSIS (IN %)

Ashok Mahindra and Glenmark Mphasis

Leyland Mahindra Pharmaceuticals
Finance
Total Assets 44.91+55.08 1.332+98.66 70+29.99 54.39+45.6
(Current+ Fixed)
Total Liabilities 48.22+6.05 47.48+36.25 17.033+13.33 2.12+21.57
(Current + Non Current) =54.27 =83.73 =30.363 =23.69
Total Equity 45.72 16.26 76.29 76.29
(Reserves and Surplus)
THANK YOU!!!